Onglyza May Increase Death Rate
Onglyza Increased Risk of All-Cause Mortality. A review published by the U.S. Food and Drug Administration (FDA) on April 10, 2015 indicates that Astra Zeneca’s key diabetes drugs—Onglyza (saxagliptin)—may be tied to "a significantly increased risk of all-cause mortality." Onglyza is a key AstraZeneca diabetes product that, in … [Read more...]
FDA Says Diabetes Drug Onglyza May be Linked to Higher Death Rate
After conducting a preliminary review of data, the U.S. Food and Drug Administration (FDA) has issued a report indicating that AstraZeneca’s diabetes drug Onglyza may be linked with an increased rate of death. According to Reuters, an FDA advisory panel will meet on April 14 to discuss he risks of Onglyza and another similar … [Read more...]
Medtronic AneuRx Stent Graft High Death Rate Prompts FDA Warning
Medtronic AneuRx Stent Graft System Have Higher Death Rates. Patients receiving Medtronic Inc's AneuRx stent graft system have higher death rates, the Food & Drug Administration (FDA) warned today. Because of the high death rate, the FDA said AneuRx should only be used following its instructions and in patients who are willing to … [Read more...]
Higher Death Rate Among Some Test Subjects Using Reminyl
Some Test Subjects Using Reminyl. Patients taking Alzheimer's drug Reminyl in a test for another use had higher death rates than those taking a placebo, Johnson & Johnson Pharmaceutical Research & Development LLC announced Friday. The patients had mild cognitive impairment, and the J&J company is no longer pursuing … [Read more...]
